Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Resmed (RSMDF) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Resmed (RSMDF) over the last 17 years, with Q4 2025 value amounting to 34.56%.

  • Resmed's EBITDA Margin rose 20100.0% to 34.56% in Q4 2025 from the same period last year, while for Dec 2025 it was 33.7%, marking a year-over-year increase of 20300.0%. This contributed to the annual value of 34.92% for FY2025, which is 48500.0% up from last year.
  • Resmed's EBITDA Margin amounted to 34.56% in Q4 2025, which was up 20100.0% from 33.43% recorded in Q3 2025.
  • Over the past 5 years, Resmed's EBITDA Margin peaked at 34.56% during Q4 2025, and registered a low of 23.66% during Q4 2023.
  • For the 5-year period, Resmed's EBITDA Margin averaged around 29.36%, with its median value being 28.99% (2021).
  • Per our database at Business Quant, Resmed's EBITDA Margin tumbled by -34500bps in 2023 and then surged by 88900bps in 2024.
  • Resmed's EBITDA Margin (Quarter) stood at 27.79% in 2021, then dropped by -2bps to 27.1% in 2022, then decreased by -13bps to 23.66% in 2023, then soared by 38bps to 32.54% in 2024, then increased by 6bps to 34.56% in 2025.
  • Its EBITDA Margin was 34.56% in Q4 2025, compared to 33.43% in Q3 2025 and 33.72% in Q2 2025.